Cyclooxygenase (COX)-1, but preferable COX-2 catalyzes the synthesis of PGE2 in several tumors, promoting angiogenesis and a suppressive inflammation in their microenvironments. Different types of cancer vaccines have been combined with COX-2 inhibitors, assuming that its particular mechanism of action will not influence the overall results of the combination. In this research, a possible relationship between the type of cancer vaccine and the outcome of the combination with a COX inhibitor was experimentally addressed. We investigated whether nonsteroidal anti-inflammatory drugs (NSAIDs) affect the immune response to vaccination. Three adjuvants were evaluated for humoral and cellular response using ovalbumin (OVA) as antigen. We evaluated also the impact of indomethacin in five tumor models and the correlation of this effect with the secretion of prostaglandin E2 (PGE2) of these cells. We finally studied the combination of indomethacin with two cancer vaccines in three different experimental settings. COX inhibitor did not interfere with dendritic cells maturation in vitro and did not affect the frequency of splenic immune cell populations in mice. However, the induction of OVA-specific antibodies is affected by the COX inhibitor but its impact on cytotoxic CD8+ T cell response is adjuvant-dependent. In contrast, the antitumor effect of the COX inhibitor in the 3LL-D122 tumor model is not mediated by CD4+ or CD8+ T cells. Interestingly, the in vivo effect observed in this model and others didn’t correlate with levels of PGE2 secretion by the tumor cell lines in vitro. Finally, the combination of a COX inhibitor with cancer vaccines may depend on the type of the cancer vaccine.
Mocellin, S., Mandruzzato, S., Bronte, V., Lise, M. and Nitti, D. (2004) Part I: Vaccines for Solid Tumours. The Lancet Oncology, 5, 681-689. https://doi.org/10.1016/S1470-2045(04)01610-9
Ostrand-Rosenberg, S., Sinha, P., Danna, E.A., Miller, S., Davis, C. and Dissanayake, S.K. (2004) Antagonists of Tumor-Specific Immunity: Tumor-Induced Immune Suppression and Host Genes That Co-Opt the Anti-Tumor Immune Response. Breast Disease, 20, 127-135. https://doi.org/10.3233/BD-2004-20113
Hussain, M., Javeed, A., Ashraf, M., Al-Zaubai, N., Stewart, A. and Mukhtar, M.M. (2012) Non-Steroidal Anti-Inflammatory Drugs, Tumour Immunity and Immunotherapy. Pharmacological Research, 66, 7-18. https://doi.org/10.1016/j.phrs.2012.02.003
Stewart, T.J. and Smyth, M.J. (2011) Improving Cancer Immunotherapy by Targeting Tumor-Induced Immune Suppression. Cancer and Metastasis Reviews, 30, 125-140. https://doi.org/10.1007/s10555-011-9280-5
Vane, J.R. (1971) Inhibition of Prostaglandin Synthesis as a Mechanism of Action for Aspirin-Like Drugs. Nature: New Biology, 231, 232-235. https://doi.org/10.1038/newbio231232a0
Lipsky, P.E. (1999) Role of Cyclooxygenase-1 and -2 in Health and Disease. The American Journal of Orthopedics, 28, 8-12.
Adelizzi, R.A. (1999) COX-1 and COX-2 in Health and Disease. The Journal of the American Osteopathic Association, 99, S7-S12. https://doi.org/10.7556/jaoa.1999.99.11.S7
Zha, S., Yegnasubramanian, V., Nelson, W.G., Isaacs, W.B. and De Marzo, A.M. (2004) Cyclooxygenases in Cancer: Progress and Perspective. Cancer Letters, 215, 1-20. https://doi.org/10.1016/j.canlet.2004.06.014
Dai, Y. and Wang, W.H. (2006) Non-Steroidal Anti-Inflammatory Drugs in Prevention of Gastric Cancer. World Journal of Gastroenterology, 12, 2884-2889. https://doi.org/10.3748/wjg.v12.i18.2884
Ulrich, C.M., Bigler, J. and Potter, J.D. (2006) Non-Steroidal Anti-Inflammatory Drugs for Cancer Prevention: Promise, Perils and Pharmacogenetics. Nature Reviews Cancer, 6, 130-140. https://doi.org/10.1038/nrc1801
Pereg, D., Kimhi, O., Tirosh, A., Orr, N., Kayouf, R. and Lishner, M. (2005) The Effect of Fermented Yogurt on the Prevention of Diarrhea in a Healthy Adult Population. American Journal of Infection Control, 33, 122-125. https://doi.org/10.1016/j.ajic.2004.11.001
Lang, S., et al. (2007) Immune Restoration in Head and Neck Cancer Patients after in Vivo COX-2 Inhibition. Cancer Immunology, Immunotherapy, 56, 1645-1652. https://doi.org/10.1007/s00262-007-0312-5
Hahn, T., et al. (2006) Short-Term Dietary Administration of Celecoxib Enhances the Efficacy of Tumor Lysate-Pulsed Dendritic Cell Vaccines in Treating Murine Breast Cancer. International Journal of Cancer, 118, 2220-2231. https://doi.org/10.1002/ijc.21616
Dovedi, S.J., Kirby, J.A., Davies, B.R., Leung, H. and Kelly, J.D. (2008) Celecoxib Has Potent Antitumour Effects as a Single Agent and in Combination with BCG Immunotherapy in a Model of Urothelial Cell Carcinoma. European Urology, 54, 621-630. https://doi.org/10.1016/j.eururo.2008.01.013
Talmadge, J.E., Hood, K.C., Zobel, L.C., Shafer, L.R., Coles, M. and Toth, B. (2007) Chemoprevention by Cyclooxygenase-2 Inhibition Reduces Immature Myeloid Suppressor Cell Expansion. International Immunopharmacology, 7, 140-151. https://doi.org/10.1016/j.intimp.2006.09.021
Lonnroth, C., et al. (2008) Preoperative Treatment with a Non-Steroidal Anti-Inflammatory Drug (NSAID) Increases Tumor Tissue Infiltration of Seemingly Activated Immune Cells in Colorectal Cancer. Cancer Immunity, 8, 5.
Haas, A.R., et al. (2006) Cycloxygenase-2 Inhibition Augments the Efficacy of a Cancer Vaccine. Clinical Cancer Research, 12, 214-222. https://doi.org/10.1158/1078-0432.CCR-05-1178
Liu, L., et al. (2012) Interleukin-17 and Prostaglandin E2 Are Involved in Formation of an M2 Macrophage-Dominant Microenvironment in Lung Cancer. Journal of Thoracic Oncology, 7, 1091-1100. https://doi.org/10.1097/JTO.0b013e3182542752
Heusinkveld, M., et al. (2011) M2 Macrophages Induced by Prostaglandin E2 and IL-6 from Cervical Carcinoma Are Switched to Activated M1 Macrophages by CD4+ Th1 Cells. The Journal of Immunology, 187, 1157-1165. https://doi.org/10.4049/jimmunol.1100889
Baratelli, F., et al. (2005) Prostaglandin E2 Induces FOXP3 Gene Expression and T Regulatory Cell Function in Human CD4+ T Cells. The Journal of Immunology, 175, 1483-1490. https://doi.org/10.4049/jimmunol.175.3.1483
Sinha, P., Clements, V.K., Fulton, A.M. and Ostrand-Rosenberg, S. (2007) Prostaglandin E2 Promotes Tumor Progression by Inducing Myeloid-Derived Suppressor Cells. Cancer Research, 67, 4507-4513. https://doi.org/10.1158/0008-5472.CAN-06-4174
Wasserman, J., et al. (1989) Immunosuppression in Irradiated Breast Cancer Patients: In Vitro Effect of Cyclooxygenase Inhibitors. The bulletin of the New York Academy of Medicine, 65, 36-44.
Motz, G.T., et al. (2014) Tumor Endothelium FasL Establishes a Selective Immune Barrier Promoting Tolerance in Tumors. Nature Medicine, 20, 607-615. https://doi.org/10.1038/nm.3541
Esquivias, P., et al. (2012) Indomethacin but Not a Selective Cyclooxygenase-2 Inhibitor Inhibits Esophageal Adenocarcinogenesis in Rats. World Journal of Gastroenterology, 18, 4866-4874. https://doi.org/10.3748/wjg.v18.i35.4866
Cho, M., et al. (2013) Aspirin Blocks EGF-Stimulated Cell Viability in a COX-1 Dependent Manner in Ovarian Cancer Cells. Journal of Cancer, 4, 671-678. https://doi.org/10.7150/jca.7118
Kim, M.S., et al. (2014) Naproxen Induces Cell-Cycle Arrest and Apoptosis in Human Urinary Bladder Cancer Cell Lines and Chemically Induced Cancers by Targeting PI3K. Cancer Prevention Research, 7, 236-245. https://doi.org/10.1158/1940-6207.CAPR-13-0288
Brunelli, C., Amici, C., Angelini, M., Fracassi, C., Belardo, G. and Santoro, M.G. (2012) The Non-Steroidal Anti-Inflammatory Drug Indomethacin Activates the eIF2alpha Kinase PKR, Causing a Translational Block in Human Colorectal Cancer Cells. Biochemical Journal, 443, 379-386. https://doi.org/10.1042/BJ20111236
Gabri, M.R., et al. (2006) Complete Antitumor Protection by Perioperative Immunization with GM3/VSSP Vaccine in a Preclinical Mouse Melanoma Model. Clinical Cancer Research, 12, 7092-7098. https://doi.org/10.1158/1078-0432.CCR-06-1075
Carr, A., et al. (2003) Immunotherapy of Advanced Breast Cancer with a Heterophilic Ganglioside (NeuGcGM3) Cancer Vaccine. Journal of Clinical Oncology, 21, 1015-1021. https://doi.org/10.1200/JCO.2003.02.124
Ramirez, B.S., et al. (2006) Active Antimetastatic Immunotherapy in Lewis Lung Carcinoma with Self EGFR Extracellular Domain Protein in VSSP Adjuvant. International Journal of Cancer, 119, 2190-2199. https://doi.org/10.1002/ijc.22085
Torrens, I., et al. (2005) Immunotherapy with CTL Peptide and VSSP Eradicated Established Human Papillomavirus (HPV) Type 16 E7-Expressing Tumors. Vaccine, 23, 5768-5774. https://doi.org/10.1016/j.vaccine.2005.07.049
Mesa, C., de Leon, J. and Fernandez, L.E. (2006) Very Small Size Proteoliposomes Derived from Neisseria meningitidis: An Effective Adjuvant for Generation of CTL Responses to Peptide and Protein Antigens. Vaccine, 24, 2692-2699. https://doi.org/10.1016/j.vaccine.2005.08.111
Mesa, C., de León, J., Rigley, K. and Fernández, L.E. (2004) Very Small Size Proteoliposomes Derived from Neisseria meningitidis: An Effective Adjuvant for Th1 Induction and Dendritic Cell Activation. Vaccine, 22, 3045-3052. https://doi.org/10.1016/j.vaccine.2004.02.010
Oliver, L., Fernández, A., Raymond, J., López-Requena, A., Fernández, L.E. and Mesa, C. (2012) Very Small Size Proteoliposomes Derived from Neisseria meningitidis: An Effective Adjuvant for Antigen-Specific Cytotoxic T Lymphocyte Response Stimulation under Leukopenic Conditions. Vaccine, 30, 2963-2972. https://doi.org/10.1016/j.vaccine.2012.02.054
Fernandez, A., et al. (2011) Inhibition of Tumor-Induced Myeloid-Derived Suppressor Cell Function by a Nanoparticulated Adjuvant. The Journal of Immunology, 186, 264-274. https://doi.org/10.4049/jimmunol.1001465
Lutz, M.B., et al. (1999) An Advanced Culture Method for Generating Large Quantities of Highly Pure Dendritic Cells from Mouse Bone Marrow. Journal of Immunological Methods, 223, 77-92. https://doi.org/10.1016/S0022-1759(98)00204-X
Brasel, K., et al. (2000) Generation of Murine Dendritic Cells from Flt3-Ligand-Supplemented Bone Marrow Cultures. Blood, 96, 3029-3039.
Estevez, F., et al. (1999) Enhancement of the Immune Response to Poorly Immunogenic Gangliosides after Incorporation into Very Small Size Proteoliposomes (VSSP). Vaccine, 18, 190-197. https://doi.org/10.1016/S0264-410X(99)00219-4
Labrada, M., et al. (2010) Direct Validation of NGcGM3 Ganglioside as a New Target for Cancer Immunotherapy. Expert Opinion on Biological Therapy, 10, 153-162. https://doi.org/10.1517/14712590903443084
Verdijk, R.M., et al., (1999) Polyriboinosinic Polyribocytidylic Acid (Poly(I:C)) Induces Stable Maturation of Functionally Active Human Dendritic Cells. The Journal of Immunology, 163, 57-61.
Whiteside, T.L. (2010) Inhibiting the Inhibitors: Evaluating Agents Targeting Cancer Immunosuppression. Expert Opinion on Biological Therapy, 10, 1019-1035. https://doi.org/10.1517/14712598.2010.482207
Harizi, H., Juzan, M., Pitard, V., Moreau, J.-F. and Gualde, N. (2002) Cyclooxygenase-2-Issued Prostaglandin e(2) Enhances the Production of Endogenous IL-10, Which Down-Regulates Dendritic Cell Functions. The Journal of Immunology, 168, 2255-2263. https://doi.org/10.4049/jimmunol.168.5.2255
Baratelli, F., et al. (2010) PGE (2) Contributes to TGF-Beta Induced T Regulatory Cell Function in Human Non-Small Cell Lung Cancer. American Journal of Translational Research, 2, 356-367.
Yamaki, K., et al. (2003) Effect of the Nonsteroidal Anti-Inflammatory Drug Indomethacin on Th1 and Th2 Immune Responses in Mice. Journal of Pharmaceutical Sciences, 92, 1723-1729. https://doi.org/10.1002/jps.10380
Hadrup, S., Donia, M. and Straten, P.T. (2013) Effector CD4 and CD8 T Cells and Their Role in the Tumor Microenvironment. Cancer Microenvironment, 6, 123-133. https://doi.org/10.1007/s12307-012-0127-6
Inoue, J. and Aramaki, Y. (2007) Cyclooxygenase-2 Inhibition Promotes Enhancement of Antitumor Responses by Transcutaneous Vaccination with Cytosine-Phosphate-Guanosine-Oligodeoxynucleotides and Model Tumor Antigen. Journal of Investigative Dermatology, 127, 614-621. https://doi.org/10.1038/sj.jid.5700656
Kas’ianenko, I.V., et al. (1992) [The Immunomodulating Role of Indomethacin in the Chemoradiation Treatment of Inoperable Patients with Lung Cancer]. Voprosy onkologii, 38, 1183-1187.
Moroz, T.D., et al. (1989) [Effect of Indomethacin on the Immunological Indices of Patients with Inoperable Stomach Cancer]. Eksp Onkol, 11, 66-68.
Mavligit, G.M., Raphael, L.S., Calvo, D.B. III and Wong, W.L. (1980) Indomethacin-Induced, Monocyte-Dependent Restoration of Local Graft-Versus-Host Reaction among Cells from Cancer Patients. Journal of the National Cancer Institute, 65, 317-320.
Liu, J.Q., et al. (2010) [Mechanistic Study of Nimesulide on Enhancing Gammadeltat Cell-Mediated Killing of Gastric Cancer Cells]. Chinese Journal of Cellular and Molecular Immunology, 26, 261-263.
Kundu, N., Walser, T.C., Ma, X. and Fulton, A.M. (2005) Cyclooxygenase Inhibitors Modulate NK Activities That Control Metastatic Disease. Cancer Immunology, Immunotherapy, 54, 981-987. https://doi.org/10.1007/s00262-005-0669-2
Lee, S.Y., et al. (2009) The Immune Tolerance of Cancer Is Mediated by IDO That Is Inhibited by COX-2 Inhibitors through Regulatory T Cells. Journal of Immunotherapy, 32, 22-28. https://doi.org/10.1097/CJI.0b013e31818ac2f7
Morecki, S., Yacovlev, E., Gelfand, Y., Trembovler, V., Shohami, E. and Slavin, S. (2000) Induction of Antitumor Immunity by Indomethacin. Cancer Immunology, Immunotherapy, 48, 613-620. https://doi.org/10.1007/s002620050009
Stolina, M., et al. (2000) Specific Inhibition of Cyclooxygenase 2 Restores Antitumor Reactivity by Altering the Balance of IL-10 and IL-12 Synthesis. The Journal of Immunology, 164, 361-370. https://doi.org/10.4049/jimmunol.164.1.361
Park, W., Oh, Y.T., Han, J.H. and Pyo, H. (2008) Antitumor Enhancement of Celecoxib, a Selective Cyclooxygenase-2 Inhibitor, in a Lewis Lung Carcinoma Expressing Cyclooxygenase-2. Journal of Experimental & Clinical Cancer Research, 27, 66. https://doi.org/10.1186/1756-9966-27-66
Pozzi, A., et al. (2004) Colon Carcinoma Cell Growth Is Associated with Prostaglandin E2/EP4 Receptor-Evoked ERK Activation. The Journal of Biological Chemistry, 279, 29797-29804. https://doi.org/10.1074/jbc.M313989200
Connolly, E.M., et al. (2002) Cyclo-Oxygenase Inhibition Reduces Tumour Growth and Metastasis in an Orthotopic Model of Breast Cancer. British Journal of Cancer, 87, 231-237. https://doi.org/10.1038/sj.bjc.6600462
Favalli, C., et al. (1980) Influence of PGE on the Immune Response in Melanoma-Bearing Mice. The Journal of Immunology, 125, 897-902.